References
- Pereira JM, Paiva JA, Re7ello J. Assessing severity of patients with community-acquired pneumonia. Semin Respir Crit Care Med. 2012;33:272–283.
- Welte T, Torres A, Nathwani D. Clinical and economic burden of community- acquired pneumonia among adults in Europe. Thorax. 2012;67:71–79.
- European Commission. Health statistics. Atlas on mortality in the European Union. Luxembourg: Office for Official Publications of the European Communities; 2008.
- Piddock LJ. The crisis of no new antibiotics what is the way forward. Lancet Infect Dis. 2012;12:249e253.
- Cillóniz C, Ewig S, Ferrer M, et al. Community-acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis. Crit Care. 2011;15:R209.
- Gutierrez F, Masia M, Rodriguez JC, et al. Community-acquired pneumonia of mixed etiology: prevalence, clinical characteristics, and outcome. Eur J Clin Microbiol Infect Dis. 2005;24:377–383.
- Gadsby NJ, Russell CD, McHugh MP, et al. Comprehensive molecular testing for respiratory pathogens in community-acquired pneumonia. Clin Infect Dis. 2016;62:817–823.
- Jain S, Self WH, Wunderink RG, et al. Community-acquired pneumonia requiring hospitalization among US adults. N Engl J Med. 2015;373(5):415–427.
- Schildgen V, Van Den Hoogen B, Fouchier R, et al. Human metapneumovirus: lessons learned over the first decade. Clin Microbiol Rev. 2011;24(4):734–754.
- Hoban DJ, Reinert RR, Bouchillon SK, et al. Global in vitro activity of tigecycline and comparator agents: tigecycline evaluation and surveillance trial 2004–2013. Ann Clin Microbiol Antimicrob. 2015;14:27.
- Nuermberger EL, Bishai WR. Antibiotic resistance in Streptococcus pneumoniae: what does the future hold? Clin Infect Dis. 2004;38(Suppl 4):SS363–SS371.
- Jacobs MR, Felmingham D, Appelbaum PC, et al. The Alexander Project 1998e2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother. 2003;52:229e46.
- Waites KB, Lysynyansky I, Bébéar CM. Antibiotic susceptibility testing and resistance in mycoplasmas of humans and animals. In: Browning G, Citti C, ed. Mollicutes: molecular biology and pathogenesis. United Kingdom: Caister Academic Press; 2014.
- Puig C, Calatayud L, Martí S, et al. Molecular epidemiology of nontypeable Haemophilus influenzae causing community-acquired pneumonia in adults. PLoS One. 2013;8(12):e 82515.
- European Center for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2014. Accessed 2016 Apr 4. Available from: http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-europe-2014.pdf
- Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America /American Thoracic Society Consensus Guidelines on the management of community- acquired pneumonia. Clin Infect Dis. 2007;44:S27–S72.
- Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64(Suppl 3):iii1- iii55.
- Postma DF, Van Werkhoven CH, Huijts SM, et al. New trends in the prevention and management of community-acquired pneumonia. Neth J Med. 2012;70(8):337–348.
- Uranga A, Espana PP, Bilbao A, et al. Duration of antibiotic treatment in community-acquired pneumonia: a multicenter randomized clinical trial. JAMA Intern Med. 2016;176:1257–1265.
- Giamarellos-Bourboulis EJ, Pechère JC, Routsi C, et al. Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis. 2008;46(8):1157–1164.
- Sligl WI, Asadi L, Eurich DT, et al. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. Crit Care Med. 2014;42(2):420–432.
- Garin N, Genné D, Carballo S, et al. β-Lactam monotherapy vs. β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med. 2014;174:1894–1901.
- Vardakas KZ, Trigkidis KK, Falagas ME. Fluoroquinolones or macrolides in combination with β-lactams in adult patients hospitalized with community acquired pneumonia: a systematic review and meta-analysis. Clin Microbiol Infect. 2017 Apr;23(4):234–241. Review.
- Rodrigo C, Mckeever TM, Woodhead M, et al. Single versus combination antibiotic therapy in adults hospitalized with community acquired pneumonia. Thorax. 2013 May;68(5):493–495.
- Asadi L, Sligl WI, Eurich DT, et al. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. Clin Infect Dis. 2012;55(3):371–380.
- Rodríguez A, Mendia A, Sirvent JM, et al. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med. 2007;35(6):1493–1498.
- Tessmer A, Welte T, Martus P, et al. Impact of intravenous β-lactam/macrolide versus β- lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia. J Antimicrob Chemother. 2009;63:1025–1033.
- Eccles S, Pincus C, Higgins B, et al. Diagnosis and management of community and hospital acquired pneumonia in adults: summary of NICE guidance. Bmj. 2014;349:g6722.
- Sader HS, Rhomberg PR, Farrell DJ, et al. Poster: antimicrobial activity of TD-1607 tested against contemporary (2010-2012) Methicillin-Resistant Staphylococcus aureus (MRSA) strains. ICAAC 2014, Washington, DC
- Theravance Biopharma Antibiotics, Inc. TD-1607 SAD Study in Healthy Subjects. In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. [cited 2016 Jan 17]. Available from: https://clinicaltrials.gov/show/NCT01791049 NLM identifier: NCT01791049.
- Theravance Biopharma Antibiotics, Inc. TD-1607 MAD study in healthy subjects. In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. [cited 2016 Jan 17]. Available from: https://clinicaltrials.gov/show/NCT01949103 NLM identifier: NCT01949103.
- Morinaka A, Tsutsumi Y, Yamada M, et al. OP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam ‘enhancer’. J Antimicrob Chemother. 2015 Oct;70(10):2779–2786.
- Butler MS, Blaskovich MAT, Cooper MA. Antibiotics in the clinical pipeline at the end of 2015. J Antibiot. 2016;70(1)3–242.
- Wang G, Xu G, Or YS, et al. New 6–11 bicyclic macrolide derivative useful in pharmaceutical composition for preventing and/or treating bacterial infection in humans. Cn101955508-A. 2011 January 26.
- EnantaPharmaceuticals. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01999725?term=EDP-322&rank=4
- Enanta Pharmaceuticals. EDP-788/EDP-322. [cited 2013 Apr 11]. Available from: http://www.enanta.com/research/antibiotics/
- Grossman TH, Fyfe C, O’Brien W, et al. Fluorocycline TP-271 is potent against complicated community-acquired bacterial pneumonia pathogens. mSphere. 2017 Feb 22; 2(1). e00004e00017
- A phase 1 study to assess the safety, tolerability and PK of IV TP-271. 2015. Available from: https://clinicaltrials.gov/ct2/show/NCT02724085?term=NCT02724085&rank=1
- A phase 1 study to assess the safety, tolerability of oral doses of TP-271. Available from: https://clinicaltrials.gov/ct2/show/NCT03024034
- Farrell JD, Sader SH, Rhomberg RP, et al. In vitro activity of lactone ketolide WCK 4873 when tested against contemporary community acquired bacterial pneumonia pathogens from a global surveillance program. MICROBE; Boston, MA. 2016. Poster number Sunday-476.
- Study to determine and compare plasma and intrapulmonary concentrations of WCK 4873 in healthy adult human subjects. 2015. Available from: https://clinicaltrials.gov/ct2/show/NCT02453529?term=WCK-4873&rank=1
- Pucci MJ, Bush K. Investigational antimicrobial agents of 2013. Clin Microbiol Rev. 2013 Oct;26(4):792–821.
- Podos SD, Thanassi JA, Leggio M, et al. Bactericidal activity of ACH-702 against nondividing and biofilm staphylococci. Antimicrobial agents and chemotherapy. Antimicrob Agents Chemother. 2012 July;56(7):3812–3818.
- Pucci MJ, Podos SD, Thanassi JA, et al. In vitro and in vivo profiles of ACH-702, an isothiazoloquinolone, against bacterial pathogens. Antimicrob Agents Chemother. 2011;55:2860–2871.
- Patel MV, De Souza NJ, Gupte SV, et al. Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models. Antimicrob Agents Chemother. 2004 Dec;48(12):4754–4761.
- https://www.clinicaltrials.gov/ct2/results?term=WCK+771&Search=Search
- De Souza Mendes CD, De Souza Antunes AM. Pipeline of known chemical classes of antibiotics review. Antibiotics. 2013;2:500–534.
- Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment: https://clinicaltrials.gov/ct2/show/NCT02244827
- Study to Determine and Compare Plasma and Intrapulmonary Pharmacokinetics of WCK 2349 in Healthy Adult Human Subjects: https://www.clinicaltrials.gov/ct2/show/NCT02253342?term=WCK-2349&rank=1
- Flamm RK, Biedenbach DJ, Sader HS, et al. KPI-10, a novel fluoroquinolone (FQ) tested against Neisseria gonorrhoeae including ciprofloxacin non-susceptible (CIP-NS) and penicillin non-susceptible (PEN-NS) strains. 2012; Abstr.52nd Intersci. Conf. Antimicrob. Agents Chemother.,abstr F-2052.
- Deane J, Simenauer A, Ge Y, et al. In vitro activity of KPI-10 against clinically important Gram-negative bacteria. 2012. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr F-2046.
- Jones TM, Johnson SW, DiMondi VP, et al. Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Infect Drug Resist. 2016 Jun 7;9:119–128.
- Morrow BJ, He W, Amsler KM, et al. In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone. Antimicrob Agents Chemother. 2010;54:1955–1964.
- Biedenbach DJ, Farrell DJ, Flamm RK, et al. Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia. Int J Antimicrob Agents. 2012;39:321–325.
- Davenport JM, Covington P, Gotfried M, et al. Summary of pharmacokinetics and tissue distribution of a broad-spectrum fluoroquinolone, JNJ-Q2. Clin Pharmacol Drug Dev. 2012;1:121–130.
- Bax BD, Chan PF, Eggleston DS, et al. Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature. 2010;466:935–940.
- Biedenbach DJ, Bouchillon SK, Hackel M, et al. In vitro activity of gepotidacin, a novel triazaacenaphthylene bacterial topoisomerase inhibitor, against a broad spectrum of bacterial pathogens. Antimicrob Agents Chemother. 2016 Jan 4;60(3):1918–1923.
- Bioavailability, Food Effect and Pharmacokinetics of Gepotidacin Tablets: https://clinicaltrials.gov/ct2/show/NCT02853435
- So W, Crandon JL, Nicolau DP. Pharmacodynamic profile of GSK2140944 against methicillin-resistant Staphylococcus aureus in a murine lung infection model. Antimicrob Agents Chemother. 2015;59:4956–4961.
- Tiffany CA, Hossain M, McDonald M, et al. 2013. Safety and pharmacokinetics of single escalating oral doses of GSK2140944, a novel bacterial topoisomerase inhibitor, abstr F-1216 Abstr 53rd Intersci Conf Antimicrob Agents Chemother.
- Jeong JW, Jung SJ, Lee HH, et al. In vitro and in vivo activities of LCB01-0371, a new oxazolidinone. Antimicrob Agents Chemother. 2010;54:5359–5362.
- Multiple Ascending Dose Study for LCB01-0371: https://clinicaltrials.gov/ct2/show/NCT01842516?term=LCB01-0371&rank=4
- Evaluation the Effect of Food on Pharmacokinetics (PK), of LCB01-0371. https//clinicaltrials. gov/ct2/show/NCT02538003?term=LCB01-0371&rank=2
- Souza Mendez C, Souza Antunes AM. Pipeline of known chemical classes of antibiotics. Antibiotics. 2013;2:500–534.
- Lemaire S, Kosowska-Shick K, Appelbaum PC, et al. Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using staphylococcus aureus, staphylococcus epidermidis, listeria monocytogenes, and legionella pneumophila. Antimicrob Agents Chemother. 2010;54:(6):2l549–2559.
- Safety and Efficacy Study of Oxazolidone to treat Pneumonia: https://clinicaltrials.gov/ct2/show/NCT00640926?term=Radezolid&rank=1
- Lawrence L, Danese P, DeVito J, et al. In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. Antimicrob Agents Chemother. 2008;52:1653–1662.
- Zhu DM, Wang W, Huang YQ, et al. 2012. Antibacterial spectrum of oxazolidinone MRX-1: potent activity against multidrug resistant Gram-positive pathogens. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother, abstr F-1497
- Gordeev MF, Yuan ZY. New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile. J Med Chem. 2014 Jun 12;57(11):4487–4497.
- MRX-I Versus Linezolid for the treatment of ABSSSI: https://clinicaltrials.gov/ct2/show/NCT02269319?term=MRX-I&rank=1
- Czaplewski L, Bax R, Clokie M, et al. Alternatives to antibiotics-a pipeline portfolio review. Lancet Infect Dis. 2016;16:239–251. https://www.drugs.com/history/solithera.html
- Kalinin DV, Holl R. LpxC inhibitors: a patent review (2010-2016). Expert Opin Ther Pat. 2017 Aug 4:1–24.
- A Multiple Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of ACHN-975 in Healthy Adults: https://clinicaltrials.gov/ct2/show/NCT01870245?term=ACHN-975&rank=1
- http://investor.cempra.com/releasedetail.cfm?ReleaseID=1005708
- Yount NY, Yeaman MR. Emerging themes and therapeutic prospects for anti-infective peptides. Annu Rev Pharmacol Toxicol. 2012;52:337–360.
- MRSA antibody therapy. http://www.xbiotech.com/clinical/mrsa. html (accessed 2015 Oct 30
- Morton B, Pennington SH, Gordon SB. Immunomodulatory adjuvant therapy in severe community-acquired pneumonia. Expert Rev Respir Med. 2014;8:587–596.
- Abedon ST, Kuhl SJ, Blasdel BG, et al. Phage treatment of human infections. Bacteriophage. 2011;1:66–85.